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Abstract About 80 % of lung cancers are carcinomas that are
classified histologically as non-small-cell lung carcinoma
(NSCLC) and targeted chemotherapy of this cancer is currently
based on sensitivity of the primary tumor to specific drugs. The
purpose of this study was to compare the levels of four serum
markers of cancer and the levels of six molecular markers
which are possibly associated with drug selection in the pri-
mary tumors and metastatic lymph nodes of 39 consecutive
NSCLC patients who were admitted to a single institution in
China. Serum markers of cancer (neuron-specific enolase,
carcinoembryonic antigen (CEA), cancer antigen 125, cytoker-
atin fragment 21-1) were measured by an automated electro-
chemiluminescence system and molecular markers (multidrug
resistance protein 1, LDL receptor-related protein, ribonucleo-
tide reductase M1, epidermal growth factor receptor, excision
repair cross-complementing gene 1, and breast cancer 1) were
measured by immunohistochemistry of the primary tumors and
metastatic lymph nodes. The results indicate that the serum
level of CEAwas higher in NSCLC patients with adenocarci-
noma relative to those with squamous cell carcinoma, but no
significant differences in the other serum markers. Expres-
sion of excision repair cross-complementing gene 1 was
significantly different in the primary tumors and metastatic
sites of NSCLC patients with adenocarcinoma, but there were
no other significant differences. This study provides an initial
step toward the development of individualized chemotherapy
of NSCLC based on measurement of molecular markers in the
primary tumors and metastatic lymph nodes.
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Introduction
Lung cancer mortality in Western countries has declined due
to a decrease in tobacco smoking in the past 20 years [1], but
the incidence of cigarette smoking in China continues to
increase and in the year 2005, an estimated 429,000 people
died from lung cancer in China [2]. The most common
treatments options for lung cancer are surgery, radiotherapy,
and chemotherapy (which may be combined with radiother-
apy and/or surgery).
There is great interest in development of targeted chemo-
therapeutic drugs that consider the unique molecular char-
acteristics of each patient’s carcinoma [2]. For example,
Brugger et al. [3] performed a large prospective biomarker
study of patients with advanced non-small cell lung cancer
(NSCLC) and reported that those with activating mutations
of epidermal growth factor receptor (EGFR) benefit most
from maintenance therapy with erlotinib. Kim et al. [4]
studied chemorefractory NSCLC patients and found that
patients with mutations in KRAS benefit most from sorafe-
nib. However, the results of these and similar studies of the
personalization of therapies for breast cancer [5], colorectal
cancer [6, 7], and ovarian cancer [8] may be limited because
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the therapy is based on molecular markers in the primary
tumor tissue, not in metastatic tissue.
Recent studies of Asian and Western patients have firmly
established that lipoprotein receptor-related protein-1, ribo-
nucleotide reductase M1 (RRM-1), EGFR, and excision
repair cross-complementing gene 1 (ERCC-1) may be use-
ful molecular markers to guide drug selection in patients
with lung cancer [9–13]. Carcinoembryonic antigen (CEA)
and carbohydrate antigen 125 (CA125) can also be used to
guide diagnosis and treatment selection and as indicators of
treatment efficacy for lung cancer [14, 15]. Cytokeratin-19
fragment (cytokeratin fragment 21-1 (CYFRA21-1)) is con-
sidered to be a sensitive marker for the diagnosis of lung
squamous cell carcinoma [16, 17]. However, there have
been no systemic studies on the possible differences in
expression of these markers in primary and metastatic
tissues.
After radical resection of primary lung tumor tissue,
residual cancer cells are mainly located in the metastatic
lymph nodes or other micro tumor tissues. Expression of
biomarkers may be different in the primary tumors and
residual metastatic lymph nodes, so these tissues may have
different drug sensitivities. The different expression of these
drug selection-associated genes at the primary tumor site
and metastatic lymph nodes might account for the var-
iable chemotherapeutic effectiveness of drugs which are
selected mainly based on gene expression in the primary
tumor.
In the present retrospective study, we examined the ex-
pression levels of these serum markers and compared the
expression of molecular markers in the primary tumor tis-
sues and metastatic lymph nodes of patients with NSCLC.
Materials and methods
Patient characteristics
This retrospective study enrolled all 39 NSCLC patients
admitted to our hospital from September 2010 to October
2011 who underwent thoracic surgery for removal of pri-
mary lesions or removal of primary and metastatic lesions
following pathological confirmation of lymph node metas-
tasis. Each patient had a primary lung cancer lesion and at
least one metastatic lymph node. In all included cases,
lymph node metastasis was limited to the ipsilateral side
lobe bronchus and the ipsilateral mediastinum (N1 and N2
stages) and could be completely removed by surgery. Post-
operative chemotherapy consisted of paclitaxel+carbopla-
tin, docetaxel+cisplatin, or gemcitabine+cisplatin. Some
patients were given targeted therapy with gefitinib. NSCLC
staging was based on the TNM Classification of Malignant
Tumors, Seventh Edition [18].
Specimen processing and staining
During thoracic surgery, the primary lesions and lymph nodes
were resected and specimens were stored in 10 % neutral
formalin for 24 h. Samples were sectioned at a thickness of
2 mm, tissue was dehydrated, embedded in paraffin, cut into
5 μm sections, and dried overnight at 37 °C.
For hematoxylin-eosin staining, tissue slides were im-
mersed in a jar with fresh 15 % H202 for 10 min, washed
thoroughly in tap water, stained in Harris’s haematoxylin for
15 min, and then washed again in tap water. A solution of
1 % aqueous eosin Y with two drops of concentrated acetic
acid was added to the jar for 5 min for counterstaining.
Tissue slides were then washed thoroughly, air dried, and
cover-slipped with Permount medium (Fischer, USA) for
microscopic examination.
Immunohistochemical staining of the six molecular
markers (multidrug resistance protein 1 (MDR-1), LRP,
RRM-1, EGFR, ERCC-1, and breast cancer 1 (BRCA-1))
was performed as described by Selvaggi et al. [19]. All
reagents and antibodies were purchased from Beijing
Golden Bridge Biotechnology Co., Ltd. and the dilutions
and applications of primary antibodies were according to the
manufacturer’s instructions. The secondary antibody was
horseradish peroxidase and the chromogenic substrate was
3,3′-diaminobenzidine.
Immunohistochemical analysis
Samples were viewed at high magnification (×400) and eight
fields of each sample were visualized for semiquantitative
analysis. The total staining score was based on a system
previously described by Fromowitz et al. [20]. In particular,
each field was scored as “0” (no staining), “1” (light yellow
staining), “2” (light brown staining), or “3” (dark brown
staining). The overall percentage of positive staining per field
was scored as “0” (≤5 % staining), “1” (6–25 % staining), “2”
(26–50 % staining), “3” (51–75 % staining), or “4” (>75 %
staining). The final score was simply the sum of these two
individual scores, and was “−” (0–1 points), “+” (2–3 points),
“++” (4–5 points), or “+++” (6–7 points).
Measurement of serum tumor markers
Serum samples were taken from all patients before surgery,
centrifuged at 2,000×g for 25 min, and stored at −20 °C
prior to analysis. The COBAS 6000 automatic electroche-
miluminescence immunoassay analyzer (Roche) was used
to measure levels of neuron-specific enolase (NSE), CEA,
CA125, CYFRA21-1. All reagents were from Roche. The
normal ranges of these markers are: NSE, 0–15 μg/mL;
CEA, 0–3.4 ng/mL; CA125, 0–35 U/mL; and CY21-1,
0–3.3 ng/mL.
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Statistical analysis
The Mann–Whitney U test was used to compare the expres-
sion of tumor markers and Fisher’s exact test was used to
compare categorical variables. Results are given as median
(interquartile range) for tumor markers and as number
(number) for categorical data. The Wilcoxon signed ranks test
was used to compare differences in the expression of molec-
ular markers in primary lesions and metastatic lymph nodes.
Spearman’s correlation coefficient was used to determine the
relationship between ERCC-1 and CEA levels. All statistical
assessments were two-sided and evaluated at the 0.05 level of
significance. Bonferroni correction was used for multiple
comparisons. Statistical analyses were performed using SPSS
15.0 statistics software (SPSS Inc, Chicago, IL, USA).
Results
We retrospectively reviewed the records of all NSCLC
cancer patients who underwent thoracic surgery in our hos-
pital from September 2010 to October 2011 (Table 1). Ulti-
mately, we examined the records of 39 patients with primary
lung cancer lesions and at least one metastatic lymph node,
all of whom underwent surgery for removal of the primary
and metastatic lesions. The patients included 30 men and
nine women and the mean age was 59.54±10.41 years
(range, 38–78 years). A total of 24 patients had squamous
cell lung carcinoma and 15 had adenocarcinoma. Twenty-
nine patients (74.4 %) were tobacco smokers.
First, we compared the expression of six molecular bio-
markers (MDR-1, LRP, RRM-1, EGFR, ERCC-1, and
BRCA-1) in the primary lung carcinoma and the metastatic
lymph nodes of patients with the two subtypes of NSCLC
(Table 2). The results indicate no significant differences in
the scores for expression of these biomarkers in patients
with these different NSCLC subtypes.
Next, we compared the expression scores of the six
molecular markers in the primary lesions and metastatic
lymph nodes of all 39 patients. Figure 1 shows representa-
tive immunohistochemical staining results for LRP, RRM-1,
EGFR, ERCC-1, BRCA-1, and MDR-1 in primary lesions
and metastatic lymph nodes. RRM-1, LRP, and MDR-1
were positively stained in cytoplasm of tumor cells in both
primary lesion and metastatic lymph node. EGFR was pos-
itively stained in cytoplasmic membrane in metastatic
lymph node but not in primary lesion. ERCC-1 was posi-
tively stained in the nucleus in metastatic lymph node but
not in primary lesion. BRCA-1 was positively stained the
cytoplasm in metastatic lymph node but not in primary
lesion. Analysis of these results indicates that ERCC-1
expression was significantly different in the primary lesions
and metastatic lymph nodes of patients with adenocarcino-
ma (Table 3). There were no other significant differences in
the expression of markers in the primary tumors and meta-
static lymph nodes.
Finally, we examined the levels of four serum markers of
cancer (NSE, CEA, CA 125, and CYFRA 21-1) in the same
39 patients (Fig. 2). The results indicate no significant
differences in NSE, cancer antigen 125 (CA-125), and
CYFA21-1, but significantly higher expression of CEA in
Table 1 Demographic and clinical characteristics of enrolled NSCLC
patients (n039)
Variable
Age, years±standard deviation 59.54±10.41
Gender, n (%)
Male 30 (76.9 %)
Female 9 (23.1 %)
Subtype of lung cancer, n (%)
Squamous cell carcinoma lung cancer 24 (61.5 %)
Adenocarcinoma lung cancer 15 (38.5 %)
Smoker, n (%) 29 (74.4 %)
Table 2 Differences in biomarker expression scores (see “Materials
and methods”) of primary lesions and metastatic lymph nodes of







Decreased 3 (12.5 %) 1 (6.7 %) 1.000
No change 18 (75.0 %) 12 (80.0 %)
Increased 3 (12.5 %) 2 (13.3 %)
LRP
Decreased 2 (8.3 %) 1 (6.7 %) 1.000
No change 15 (62.5 %) 10 (66.7 %)
Increased 7 (29.2 %) 4 (26.7 %)
RRM-1
Decreased 5 (20.8 %) 6 (40.0 %) 0.200
No change 17 (70.8 %) 6 (40.0 %)
Increased 2 (8.3 %) 3 (20.0 %)
EGFR
Decreased 5 (20.8 %) 4 (26.7 %) 0.907
No change 14 (58.3 %) 8 (53.3 %)
Increased 5 (20.8 %) 3 (20.0 %)
ERCC-1
Decreased 6 (25.0 %) 6 (40.0 %) 0.389
No change 16 (66.7 %) 9 (60.0 %)
Increased 2 (8.3 %) 0 (0.0 %)
BRCA-1
Decreased 1 (4.2 %) 3 (20.0 %) 0.062
No change 21 (87.5 %) 8 (53.3 %)
Increased 2 (8.3 %) 4 (26.7 %)
P values are from Fisher’s exact test
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Fig. 1 Representative
immunohistochemical staining
results for LRP, RRM-1, EGFR,
and ERCC-1, BRCA-1, and
MDR-1 in a primary tumor
(adenocarcinoma) and a meta-
static lymph node (squamous
cell carcinoma), ×400. Arrows
indicate strong positive staining
in the cytoplasma and the
nucleus
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patients with adenocarcinoma lung cancer relative to those
with squamous cell lung carcinoma (p00.002). In addition,
the correlations between ERCC-1and CEA levels in the
primary lesions (Fig. 3a, P00.692) and metastatic lymph
nodes (Fig. 3b, P00.498) were not statistically significant.
Discussion
We studied 39 consecutive NSCLC patients and measured
the expression of six molecular markers (MDR-1, LRP,
RRM-1, EGFR, ERCC-1, BRCA-1) in their primary tumors
and metastatic lymph nodes and four well-known serum
markers for cancer (NSE, CEA, CA-125, CYFRA 21-1).
Our results indicate that ERCC had significantly different
expression in the primary tumors and metastatic lymph
nodes of patients with adenocarcinoma. However, there
were no other significant differences in the expression of
the markers in the primary tumors and metastatic lymph
nodes. Our measurements of serum markers indicated that
serum CEA level was significantly higher in patients with
adenocarcinoma rather than squamous cell carcinoma, but
Table 3 Expression of molecu-
lar markers in the primary
lesions and metastatic lymph
nodes of patients with different
subtypes of NSCLC
P values are from Wilcoxon
signed ranks test. The scoring
system (−, ±, +, ++, +++) is
described in the “Materials and
Methods” section
*P<0.05, significant difference











− 20 (83.3) 20 (83.3) 0.739 13 (86.7) 14 (93.3) 0.564
± 3 (12.5) 3 (12.5) 0 (0.0) 0 (0.0)
+ 0 (0.0) 1 (4.2) 2 (13.3) 1 (6.7)
++ 1 (4.2) 0 (0.0) 0 (0.0) 0 (0.0)
+++ 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
LRP
− 13 (54.2) 15 (62.5) 0.140 0 (0.0) 1 (6.7) 0.480
± 0 (0.0) 1 (4.2) 0 (0.0) 0 (0.0)
+ 7 (29.2) 6 (25.0) 4 (26.7) 4 (26.7)
++ 4 (16.7) 2 (8.3) 4 (26.4) 3 (20.0)
+++ 0 (0.0) 0 (0.0) 7 (46.7) 0 (0.0)
RRM-1
− 5 (20.8) 4 (16.7) 0.206 3 (20.0) 3 (20.0) 0.151
± 0 (0.0) 0 (0.0) 1 (6.7) 0 (0.0)
+ 9 (37.5) 9 (37.5) 3 (20.0) 2 (13.3)
++ 6 (25.0) 5 (20.8) 5 (33.3) 5 (33.3)
+++ 4 (16.7) 6 (25.0) 3 (20.0) 5 (33.3)
EGFR
− 2 (8.3) 3 (12.5) 0.782 4 (26.7) 2 (13.3) 0.380
± 1 (4.2) 0 (0.0) 0 (0.0) 1 (6.7)
+ 3 (12.5) 4 (16.7) 2 (13.3) 2 (13.3)
++ 14 (58.3) 12 (50.0) 6 (40.0) 7 (46.7)
+++ 4 (16.7) 5 (20.8) 3 (20.0) 3 (20.0)
ERCC-1
− 18 (75.0) 17 (70.8) 0.201 11 (73.3) 8 (53.3) 0.026*
± 1 (4.2) 2 (8.3) 2 (13.3) 1 (6.7)
+ 3 (12.5) 0 (0.0) 2 (13.3) 4 (26.7)
++ 2 (8.3) 3 (12.5) 0 (0.0) 2 (13.3)
+++ 0 (0.0) 2 (8.3) 0 (0.0) 0 (0.0)
BRCA-1
− 17 (70.8) 19 (79.2) 1.000 8 (53.3) 8 (53.3) 0.260
± 2 (8.3) 1 (4.2) 0 (0.0) 4 (26.7)
+ 5 (20.8) 3 (12.5) 7 (46.7) 3 (20.0)
++ 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
+++ 0 (0.0) 1 (4.2) 0 (0.0) 0 (0.0)
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there were no other differences in expression of the serum
markers that we measured. These results provide an initial
step toward the development of lung cancer therapy that is
based on measurement of the expression of biomarkers in
the primary tumor tissue, metastatic lymph nodes, and
serum.
Individualized treatment of cancer is believed to have
great promise and many clinical and experimental studies
have used tumor-specific molecular markers to identify dif-
ferences in patients in order to better estimate prognosis and
select treatments [21]. This motivated our comparison of
the expression of six molecular markers in the primary
tumors and metastatic lymph nodes of patients with
NSCLC.
We carefully selected the markers that we studied. LRP is
the major vault protein whose elevated expression is associ-
ated with poor response to chemotherapy [22, 23]. Rybarova
et al. [24] reported that LRP expression was significantly
greater in patients with NSCLC than in those with SCLC,
which is in line with the general clinical finding that untreated
SCLC is more chemosensitive than untreated NSCLC. Our
results indicated no significant differences in LRP expression
in primary and metastatic lesions of patients with NSCLC.
Ribonucleotide reductase is a rate-limiting enzyme for the
synthesis of DNA and has two subunits, RRM-1 and RRM-
2. The RRM-1 gene is a target of numerous chemotherapeutic
agents [25]. Previous clinical studies have shown that lung
cancer patients with low levels of RRM-1 mRNA are more
sensitive to gemcitabine and have longer survival times
[26–28] and the recent US National Comprehensive Cancer
Treatment Access Coalition (NCCN) NSCLC treatment
guidelines recommend measurement of RRM-1 expression
before implementation of gemcitabine therapy in NSCLC
patients [29]. Our results indicated no significant differences
in RRM-1 expression in primary and metastatic lesions of
patients with NSCLC. EGFR is a receptor tyrosine kinase
involved in activation of transcription factors that regulate
gene transcription, cell migration, adhesion, differentiation,
and apoptosis [30]. EGFR-positive lung cancer patients are
more responsive to Iressa and Tarceva [31], which are classi-
fied as EGFR tyrosine kinase inhibitors. Our results indicated
no significant differences in EGFR expression in primary and
metastatic lesions of patients with NSCLC. ERCC-1 is a key
enzyme in nucleotide excision repair and mutations in this
gene appear to play a role in cancer pathogenesis [13]. Previ-
ous clinical studies have demonstrated that downregulation of
ERCC-1 in NSCLC patients is associated with increased
sensitivity to platinum-based chemotherapy [32, 33]. The
Fig. 2 Expression of serum tumor markers (NSE, CEA, CA 125, and CYFRA 21-1) in patients with different subtypes of NSCLC
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recent NCCN NSCLC treatment guidelines recommend mea-
surement of ERCC-1 before implementation of platimum-
based chemotherapy in NSCLC patients [29]. Interestingly,
we found significantly different expression of ERCC-1 in the
metastatic and primary lesions of NSCLC patients with ade-
nocarcinoma. Das et al. [34] recently reported that their use of
a novel circulating tumor cell (CTC) blood test to measure
ERCC-1 expression in CTCs in patients with metastatic
NSCLC. They found that low expression of ERCC1
on CTCs correlated with progression-free survival.
These findings provide general support for our finding
of the importance of measuring markers outside the primary
tumor.
Previous studies indicate that genetic testing should be
performed on lung cancer patients and that the treatment
should be customized according to the results. Taken togeth-
er, our results indicate that MDR-1, LRP, RRM-1, EGFR,
and BRCA-1 levels were similar in the primary and meta-
static lesions of all NSCLC patients. This was not surpris-
ing, because these lesions ultimately have the same source.
However, ERCC-1 levels were significantly different in the
primary and metastatic lesions. At present, the cause and
clinical significance of this difference is uncertain. It is
possible that the cells of the primary lung tumor which
become metastatic are genetically unique from the bulk of
the primary tumor cells [35]. We suggest that future studies
measure ERCC-1 in primary and metastatic lesions and
determine the association of altered ERCC-1 levels with
patient prognosis and responsiveness to different chemo-
therapy regimens.
Our measurement of serum markers of cancer indicated
that NSE, CA-125, and CYA 21-1 levels were similar in
NSCLC patients with squamous cell carcinoma and adeno-
carcinoma. However, CEA levels were significantly higher
in NSCLC patients with adenocarcinoma. Again, we sug-
gest that future studies measure serum CEA levels in
NSCLC patients and determine the association of CEA 1
levels with patient prognosis and responsiveness to different
chemotherapy regimens. But we did not find any relation-
ship between ERCC-1 and CEA levels in the primary tumor
tissues or in the metastatic lymph nodes. ERCC-1 and CEA
might be associated with lung cancer development and its
metastasis through different mechanism. How these two
molecules involved in the lung cancer development
and metastasis should be further investigated in future
study.
Our study had several limitations that should be noted.
First, our sample size was relatively small, limiting the
statistical power of our results. Second, this study was
performed at a single institution, so the results should not
be generalized to other institutions. Third, this was a retro-
spective study, so there may have been significant selection
bias.
At present, the onset and pathogenesis of NSCLC are not
completely understood and predictions of prognosis are not
very reliable. The use of molecular markers to guide treat-
ment of this cancer is currently in the initial stages. Our
results suggest that expression of ERCC-1 was significantly
different in primary tumors and metastatic sites of NSCLC
patients with adenocarcinoma and that the serum level of
CEA was significantly higher in NSCLC patients with ade-
nocarcinoma. Large-scale multi-institutional prospective
studies are needed to validate these findings before we
can make definitive suggestions about the use of indi-
vidualized treatment based on measurement of these
biomarkers in primary tumors and metastatic lymph
nodes.
Acknowledgments This study was supported by the General Hospital
of the Chinese People’s Liberation Army. We thank all our patients and
their families, as well as Dr. Cui Dejian and Dr. Yao Yongming, profes-
sors of the First Affiliated Hospital of General Hospital of the Chinese
People’s Liberation Army.
Conflicts of interest None
Fig. 3 The correlation between ERCC-1 and CEA levels in the pri-
mary tumor tissue (a) and the metatstatic lymph nodes (b)
Tumor Biol. (2012) 33:2209–2216 2215
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
References
1. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer:
epidemiology, risk factors, treatment, and survivorship. Mayo Clin
Proc. 2008;83:584–94.
2. Zhang H, Cai B. The impact of tobacco on lung health in China.
Respirology. 2003;8:17–21.
3. Brugger W, Triller N, Blasinska-Morawiec M, et al. Prospective
molecular marker analyses of EGFR and KRAS from a randomized,
placebo-controlled study of erlotinib maintenance therapy in ad-
vanced non-small-cell lung cancer. J Clin Oncol. 2011;29:4113–20.
4. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: person-
alizing therapy for lung cancer. Cancer Discov. 2011;1:44–53.
5. Acharya CR, Hsu DS, Anders CK, et al. Gene expression signa-
tures, clinicopathological features, and individualized therapy in
breast cancer. JAMA. 2008;299:1574–87.
6. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN,
BRAF, and EGFR status in determining benefit from cetuximab
therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol.
2009;27:5924–30.
7. Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al. Biomarkers
predicting clinical outcome of epidermal growth factor receptor-
targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst.
2009;101:1308–24.
8. Kim HS, Park NH, Chung HH, et al. Serum CA-125 level after 6
cycles of primary adjuvant chemotherapy is a useful prognostic
factor for complete responders’ survival in patients with advanced
epithelial ovarian cancer. Onkologie. 2008;31:315–20.
9. Wu GP, Ba J, Zhao YJ, Wang EH. Diagnostic value of CEA,
CYFRA 21-1, NSE and CA 125 assay in serum and pleural
effusion of patients with lung cancer. Acta Cytol. 2007;51:679–80.
10. Kurzrock R, Gabrail NY, Chandhasin C, et al. Safety, pharmaco-
kinetics and activity of grn1005, a novel conjugate of angiopep-2,
a peptide facilitating brain penetration, and paclitaxel, in patients
with advanced solid tumors. Mol Cancer Ther. 2012;11:308–16.
11. Andrews TD, Baird JW, Wallace WA, Harrison DJ. Routinely
obtained diagnostic material as a source of RNA for personalized
medicine in lung cancer patients. J Thorac Oncol. 2011;6:884–8.
12. Janku F, Garrido-Laguna I, Petruzelka LB, et al. Novel therapeutic
targets in non-small cell lung cancer. J Thorac Oncol. 2011;6:1601–12.
13. Tufman A, Huber RM. Biological markers in lung cancer: a
clinician’s perspective. Cancer Biomark. 2010;6:123–35.
14. Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as
tumor marker in lung cancer. Lung Cancer. 2012;76:138–43.
15. Schneider J. Tumor markers in detection of lung cancer. Adv Clin
Chem. 2006;42:1–41.
16. Matsuoka K, Sumitomo S, Nakashima N, Nakajima D, Misaki N.
Prognostic value of carcinoembryonic antigen and CYFRA21-1 in
patients with pathological stage I non-small cell lung cancer. Eur J
Cardiothorac Surg. 2007;32:435–9.
17. Buccheri G, Ferrigno D. Cytokeratin-derived markers of lung
cancer. Expert Rev Mol Diagn. 2001;1:315–22.
18. Sobin LH, Gospodarowicz MK, Wittekind C, editors. TNM clas-
sification of malignant tumours. 7th ed. West Sussex: Wiley; 2009.
19. Selvaggi G, Scagliotti GV. Histologic subtype in NSCLC: does it
matter? Oncology. 2009;23:1133–40.
20. Fromowitz FB, Viola MV, Chao S, et al. ras p21 expression in the
progression of breast cancer. Hum Pathol. 1987;18:1268–75.
21. Dienstmann R, Martinez P, Felip E. Personalizing therapy with
targeted agents in non-small cell lung cancer. Oncotarget.
2011;2:165–77.
22. Scheffer GL, Wijngaard PL, Flens MJ, et al. The drug resistance-
related protein LRP is the human major vault protein. Nat Med.
1995;1:578–82.
23. Scheffer GL, Schroeijers AB, Izquierdo MA, et al. Lung
resistance-related protein/major vault protein and vaults in
multidrug-resistant cancer. Curr Opin Oncol. 2000;12:550–6.
24. Rybárová S, Hajduková M, Hodorová I, et al. Expression of the
multidrug resistance-associated protein 1 (MRP1) and the lung
resistance-related protein (LRP) in human lung cancer. Neoplasma.
2004;51:169–74.
25. Hashemy SI, Ungerstedt JS, Zahedi Avval F, Holmgren A. Motex-
afin gadolinium, a tumor-selective drug targeting thioredoxin re-
ductase and r ibonucleot ide reductase . J Biol Chem.
2006;281:10691–7.
26. Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in
vitro and in vivo efficacy of gemcitabine and platinum in non-
small-cell lung cancer. J Clin Oncol. 2006;24:4731–7.
27. Rosell R, Danenberg KD, Alberola V, et al. Ribonucleotide reduc-
tase messenger RNA expression and survival in gemcitabine/cis-
platin-treated advanced non-small cell lung cancer patients. Clin
Cancer Res. 2004;10:1318–25.
28. Davidson JD, Ma L, Flagella M, et al. An increase in the expres-
sion of ribonucleotide reductase large subunit 1 is associated with
gemcitabine resistance in non-small cell lung cancer cell lines.
Cancer Res. 2004;64:3761–6.
29. NCCNClinical Practice Guidelines in Oncology for NSCLC.V2.2009
http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
Accessed: May 28, 2012.
30. Cunningham D, Humblet Y, Siena S, Khayat D, et al. Cetuximab
monotherapy and cetuximab plus irinotecan in irinotecan-
refractory metastatic colorectal cancer. N Engl J Med.
2004;351:337–45.
31. Gupta R, Dastane AM, McKenna Jr R, Marchevsky AM. The
predictive value of epidermal growth factor receptor tests in
patients with pulmonary adenocarcinoma: review of current “best
evidence” with meta-analysis. Hum Pathol. 2009;40:356–65.
32. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in
non-small-cell lung cancer and cisplatin-based adjuvant chemo-
therapy. N Engl J Med. 2006;355:983–91.
33. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression
correlates with prolonged survival after cisplatin plus gemcitabine
chemotherapy in non-small cell lung cancer. Clin Cancer Res.
2002;8:2286–91.
34. Das M, Riess JW, Frankel P, et al. ERCC1 expression in circulating
tumor cells (CTCs) using a novel detection platform correlates
with progression-free survival (PFS) in patients with metastatic
non-small-cell lung cancer (NSCLC) receiving platinum chemo-
therapy. Lung Cancer. 2012;77:421–6.
35. Braun S, Naume B. Circulating and disseminated tumor cells. J
Clin Oncol. 2005;23:1623–6.
2216 Tumor Biol. (2012) 33:2209–2216
